BioXconomy is part of the Informa Connect Division of Informa PLC
Informa PLC
|
ABOUT US
|
INVESTOR RELATIONS
|
TALENT
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
About
Events
Advertise
Stay Updated
Stay Updated
Investment
Related Topics
VC/PE
Seed Funding
IPOs
Recent in
Investment
See All
dollar bills
Investment
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
by
Millie Nelson
Jan 15, 2025
2 Min Read
JPM written on wooden blocks in blue
Investment
JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx
JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx
by
Millie Nelson
Jan 14, 2025
2 Min Read
Innovation
Related Topics
Hubs
Academic Research
R&D Technology
Recent in
Innovation
See All
Image of China banknotes with a magnifying glass indicating dealmaking in Asia
Hubs
Eyes on Asia: BIOSECURE, Merck & Hansoh, Roche adds ADC, and Samsung
Eyes on Asia: BIOSECURE, Merck & Hansoh, Roche adds ADC, and Samsung
by
Dan Stanton
Jan 8, 2025
5 Min Read
UK FLAG
Innovation
Charles River launches UK incubator program
Charles River launches UK incubator program
by
Millie Nelson
Dec 28, 2024
2 Min Read
Partnering
Related Topics
Licensing
M&A
Deals
Best Practices
Recent in
Partnering
See All
Novo Nordisk logo on a window
Business Strategy
Novo on the ‘ins and outs’ of its nucleic acid growth
Novo on the ‘ins and outs’ of its nucleic acid growth
by
Dan Stanton
Jan 16, 2025
5 Min Read
dollar bills
Investment
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
by
Millie Nelson
Jan 15, 2025
2 Min Read
Business Strategy
Related Topics
Scaling/Commercialization
Growth Strategy
ESG
Outsourcing
Legal
Recent in
Business Strategy
See All
Novo Nordisk logo on a window
Business Strategy
Novo on the ‘ins and outs’ of its nucleic acid growth
Novo on the ‘ins and outs’ of its nucleic acid growth
by
Dan Stanton
Jan 16, 2025
5 Min Read
dollar bills
Investment
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
by
Millie Nelson
Jan 15, 2025
2 Min Read
Home
Millie Nelson
Millie Nelson
Editor, BioXconomy
Latest from Millie Nelson
dollar bills
Investment
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
by
Millie Nelson
Jan 15, 2025
2 Min Read
JPM written on wooden blocks in blue
Investment
JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx
JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx
by
Millie Nelson
Jan 14, 2025
2 Min Read
All from Millie Nelson
Innovation
Charles River launches UK incubator program
Charles River launches UK incubator program
Dec 28, 2024
|
2 Min Read
by
Millie Nelson
, Editor
Investment
Chroma Medicine and Nvelop Tx merge to launch nChroma Bio with $75m
Chroma Medicine and Nvelop Tx merge to launch nChroma Bio with $75m
Dec 23, 2024
|
2 Min Read
by
Millie Nelson
, Editor
Investment
Antag bags $84M in series A funding to drive obesity candidate to the clinic
Antag bags $84M in series A funding to drive obesity candidate to the clinic
Dec 19, 2024
|
2 Min Read
by
Millie Nelson
, Editor
Investment
AbbVie forks out $200m to buy Roche spin-out Nimble
AbbVie forks out $200m to buy Roche spin-out Nimble
Dec 19, 2024
|
2 Min Read
by
Millie Nelson
, Editor
Investment
‘Luck only comes to the most prepared people,’ says AltruBio CEO
‘Luck only comes to the most prepared people,’ says AltruBio CEO
Dec 13, 2024
|
4 Min Read
by
Millie Nelson
, Editor
Partnering
Three’s a crowd? Not in this partnership, says MicroFluidX
Three’s a crowd? Not in this partnership, says MicroFluidX
Dec 9, 2024
|
4 Min Read
by
Millie Nelson
, Editor
Innovation
Bayer expands global incubator network with Germany hub
Bayer expands global incubator network with Germany hub
Dec 9, 2024
|
2 Min Read
by
Millie Nelson
, Editor
Innovation
To protect the future of healthcare, we need to be data-driven
To protect the future of healthcare, we need to be data-driven
Dec 4, 2024
|
2 Min Read
by
Millie Nelson
, Editor
Innovation
LSX awards the crème de la crème of dealmaking
LSX awards the crème de la crème of dealmaking
Dec 3, 2024
|
2 Min Read
by
Millie Nelson
, Editor
Investment
Novartis chases muscular dystrophy treatment with Kate Tx buy
Novartis chases muscular dystrophy treatment with Kate Tx buy
Nov 27, 2024
|
2 Min Read
by
Millie Nelson
, Editor
Business Strategy
Lessons and blessings: The Novo Nordisk way
Lessons and blessings: The Novo Nordisk way
Nov 22, 2024
|
2 Min Read
by
Millie Nelson
, Editor
Investment
From Series A to B: Navigating the transition from promise to proof
From Series A to B: Navigating the transition from promise to proof
Nov 20, 2024
|
3 Min Read
by
Millie Nelson
, Editor
Partnering
Picky pharma prone to better proven partners amid dealmaking downturn
Picky pharma prone to better proven partners amid dealmaking downturn
Nov 19, 2024
|
3 Min Read
by
Millie Nelson
, Editor
Innovation
Nonprofit looks to bring tomorrow’s science into today’s classrooms
Nonprofit looks to bring tomorrow’s science into today’s classrooms
Nov 11, 2024
|
4 Min Read
by
Millie Nelson
, Editor
Seed Funding
Europe’s adversity to risk is why the US is ahead, say experts
Europe’s adversity to risk is why the US is ahead
Nov 5, 2024
|
3 Min Read
by
Millie Nelson
, Editor
Investment
Call for specific female health funding to tackle biotech finance gender gap
Call for specific female health funding to tackle biotech finance gender gap
Oct 30, 2024
|
2 Min Read
by
Millie Nelson
, Editor
Partnering
AbbVie forks out $1.4bn to buy Alzheimer’s therapy developer Aliada
AbbVie forks out $1.4bn to buy Aliada
Oct 29, 2024
|
2 Min Read
by
Millie Nelson
, Editor
Investment
What’s your secret sauce? VC’s on what makes a compelling pitch
VC’s on what makes a compelling pitch
Oct 24, 2024
|
3 Min Read
by
Millie Nelson
, Editor
Innovation
From east to west: Lilly plans incubators in China and UK
From east to west: Lilly plans incubators in China and UK
Oct 18, 2024
|
2 Min Read
by
Millie Nelson,
Richard Daverman
Investment
The rise of radiopharmaceuticals sees big pharma back Aktis’ $175m Series B
The rise of radiopharmaceuticals sees big pharma back Aktis’ $175m Series B
Oct 17, 2024
|
2 Min Read
by
Millie Nelson
, Editor
Business Strategy
Build trust by making healthcare fairer and more equitable, say experts
Build trust by making healthcare fairer and more equitable, say experts
Oct 14, 2024
|
3 Min Read
by
Millie Nelson
, Editor
Business Strategy
The sustainability series: Reflect, rethink, and reform
The sustainability series: Reflect, rethink, and reform
Oct 11, 2024
|
14 Min Read
by
Millie Nelson
, Editor
Partnering
Novo’s hunt for genetic med tech drove $600m NanoVation pact
Novo’s hunt for genetic med tech drove $600m NanoVation pact
Oct 1, 2024
|
2 Min Read
by
Millie Nelson
, Editor
Investment
$325 million Series C funding in its Arsenal (Biosciences)
$325 million Series C funding in its Arsenal (Biosciences)
Sep 25, 2024
|
1 Min Read
by
Millie Nelson
, Editor
Partnering
Want to be a partner of choice? Distinguish yourself in the space
Want to be a partner of choice? Distinguish yourself in the space
Sep 25, 2024
|
4 Min Read
by
Millie Nelson
, Editor
Partnering
To be truly great you need to partner, says J&J
To be truly great you need to partner, says J&J
Sep 25, 2024
|
7 Min Read
by
Millie Nelson
, Editor
Partnering
RayzeBio: A Christmas to remember
RayzeBio: A Christmas to remember
Sep 25, 2024
|
3 Min Read
by
Millie Nelson
, Editor
Partnering
Prometheus and Merck: Under the bonnet of the largest pre-Phase III M&A deal
Under the bonnet of the largest pre-Phase III M&A deal
Sep 25, 2024
|
6 Min Read
by
Millie Nelson
, Editor
Partnering
Bayer and NextRNA: One partnership, two oncology programs
Bayer and NextRNA: One partnership, two oncology programs
Sep 25, 2024
|
3 Min Read
by
Millie Nelson
, Editor
Partnering
BioNTech: Partnerships are key to deliver drugs at scale
BioNTech: Partnerships are key to deliver drugs at scale
May 20, 2024
|
2 Min Read
by
Millie Nelson
, Editor
Innovation
From healthcare to health: 'No country can do this alone,' say experts in UAE
'No country can do this alone,' say experts in UAE
May 14, 2024
|
2 Min Read
by
Millie Nelson
, Editor
Business Strategy
Building successful teams in biotech: “The future is female and very colorful”
Building successful teams in biotech
May 7, 2024
|
2 Min Read
by
Millie Nelson
, Editor
Partnering
Perfect match: Picking your CDMO is like a marriage, says Bayer
Picking your CDMO is like a marriage, says Bayer
Apr 11, 2024
|
2 Min Read
by
Millie Nelson
, Editor
Previous
1
2
Next
BIO-EUROPE COVERAGE
Novo Nordisk sign
Business Strategy
Lessons and blessings: The Novo Nordisk way
Lessons and blessings: The Novo Nordisk way
Michael May, PhD, President, CCRM discusses Canada as a place for life sciences in this video.
Hubs
Bridging AI & Life Sciences, Why Investing in Canada Should Be Your Next Move
Bridging AI & Life Sciences, Why Investing in Canada Should Be Your Next Move
Shaking hands
Partnering
Picky pharma prone to better proven partners amid dealmaking downturn
Picky pharma prone to better proven partners amid dealmaking downturn
Hervé Ansanay, Biotech Alliance Manager, discusses the features of the RESEAU SATT - SATT NETWORK
Hubs
RESEAU SATT, the Best of French Deep Tech
RESEAU SATT, the Best of French Deep Tech
photo of Golden Gate Bridge over the bay
Jan 13 - Jan 15, 2025
Jan 13 - Jan 15, 2025
An all-inclusive healthcare conference at Hilton Union Square, San Francisco
Register
Latest
Novo Nordisk logo on a window
Business Strategy
Novo on the ‘ins and outs’ of its nucleic acid growth
Novo on the ‘ins and outs’ of its nucleic acid growth
dollar bills
Investment
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
JPM written on wooden blocks in blue
Investment
JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx
JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx
Subscribe to Our Newsletters
Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.
Stay Updated